Author

Kenneth S Wu

Observed name: Kenneth Wu

Observed institutions: Poznan University of Medical Sciences, University of Cologne, University of California, Irvine, St James's University Hospital, University of Łódź, BeiGene (China), Dana-Farber Cancer Institute

OpenAlex ID: A5072909010

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

2022 · Jennifer R. Brown, Barbara Eichhorst, et al. · New England Journal of Medicine · 494

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

2022 · Peter Hillmen, Barbara Eichhorst, et al. · Journal of Clinical Oncology · 98

ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

2020 · Peter Hillmen, Jennifer R Brown, et al. · Future Oncology · 80

Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study

2021 · Gavin Cull, Jan A. Burger, et al. · British Journal of Haematology · 39

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

2023 · Jennifer R. Brown, Barbara F. Eichhorst, et al. · Blood · 24

CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

2025 · Meghan Thompson, Constantine Tam, et al. · Blood · 2

Oral versus intravenous administration of cyclophosphamide: a case report

2008 · Kenneth S Wu, Chung Kwok, et al. · Cases Journal · 1

Works count: 8

Citation count: 738

H-index: 5

I10-index: 5